Adaptimmune Therapeutics PLC Business Operations Contracts & Agreements
16 Contracts & Agreements
- Collaboration Agreements (5 contracts)
- Development Agreements (3)
- Services Agreements (5)
- Termination Agreements (1)
- Voting Agreements (2)
- Termination and Transfer Agreement made and effective as of April 6, 2023 by and between Adaptimmune Limited and GlaxoSmithKline Intellectual Property Development Ltd (Filed With SEC on April 11, 2023)
- Form of Voting and Support Agreement, dated as of March 5, 2023, by and among Adaptimmune, TCR2 and certain shareholders of Adaptimmune (Filed With SEC on March 6, 2023)
- Form of Voting and Support Agreement, dated as of March 5, 2023, by and among Adaptimmune, TCR2 and certain stockholders of TCR2 (Filed With SEC on March 6, 2023)
- Amendment Agreement No. 8 made and effective as of December 19, 2022 by and between Adaptimmune Limited and GlaxoSmithKline Intellectual Property Development Ltd (Filed With SEC on December 20, 2022)
- Collaboration and License Agreement, dated January 13, 2020, by and between Universal Cells, Inc. and Adaptimmune Limited (Filed With SEC on February 27, 2020)
- Variation Agreement dated as of February 17, 2020 by and between La Fosse Associates Limited, GAR-1 Business Advisory Services and Adaptimmune, LLC (Filed With SEC on February 18, 2020)
- Service Agreement dated as of February 17, 2020 by and between Adaptimmune Limited and Gavin Wood (Filed With SEC on February 18, 2020)
- Agreement dated as of September 30, 2019 by and between La Fosse Associates Limited, GAR-1 Business Advisory Services and Adaptimmune, LLC (Filed With SEC on November 6, 2019)
- Collaboration Agreement dated as of August 26, 2019 by and among Adaptimmune Limited and Noile-Immune Biotech, Inc (Filed With SEC on August 27, 2019)
- Collaboration Agreement dated May 14, 2019 between Adaptimmune Limited and AIS Operating Co., Inc., f/k/a Alpine Immune Sciences, Inc (Filed With SEC on August 1, 2019)
- Amendment Agreement No. 6, dated July 20, 2018 between Adaptimmune Limited and GlaxoSmithKline Intellectual Property Development Ltd (Filed With SEC on August 2, 2018)
- Collaboration Agreement, dated January 5, 2018, between Adaptimmune Limited and Cell Therapy Catapult Limited (Filed With SEC on March 15, 2018)
- Amendment Agreement No. 5, dated September 7, 2017 between Adaptimmune Limited and GlaxoSmithKline Intellectual Property Development Ltd (Filed With SEC on November 2, 2017)
- DATED 10 March 2017 (1) ADAPTIMMUNE THERAPEUTICS PLC and (2) J.J. NOBLE SERVICE AGREEMENT (Filed With SEC on March 13, 2017)
- CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT by and between Merck Sharp & Dohme B.V., and Adaptimmune Limited Dated: October 27th, 2016 (Filed With SEC on November 10, 2016)
- SERVICES AGREEMENT (Filed With SEC on November 10, 2016)
